Steven Kase
Otolaryngology · White Plains, NYNPI 1376582924
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Optinose US, Inc. at 33.4% of the total. Reporting peaked in 2023 at $751 and has fallen 71.8% since, to $212 in 2024.
Across 105 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$791
- GSK$769
- Novartis$187
- Sanofi$122
- Stryker$106
- Inspire Medical Systems, Inc.$87
- plus $303 from 11 others
What the payments were for
- Food & beverage$2,366100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 40 | $791 |
| GSK | 28 | $769 |
| Novartis | 10 | $187 |
| Sanofi | 5 | $122 |
| Stryker | 3 | $106 |
| Inspire Medical Systems, Inc. | 3 | $87 |
| AbbVie(2 entities) | 2 | $56 |
| Regeneron Healthcare Solutions, Inc. | 3 | $54 |
| AstraZeneca | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $26 |
| Blueprint Medicines Corporation | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Smith+Nephew | 1 | $18 |
| Pfizer | 1 | $15 |
| Acelrx Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $13 |
How this compares
$2,366 in reported general payments places this provider in the 65th percentile of 701 otolaryngology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 29 | $607 |
| Famotidine | 48 | $543 |
| Montelukast Sodium | 31 | $417 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in White Plains
- Nitin BhatiaWhite Plains$120K
- Robert KellmanSyracuse$2.5M
- Roheen RaithathaNew York$830K
- Nora PerkinsAlbany$300K
- Moshe EphratNew Hyde Park$250K
- Gavin SetzenAlbany$243K
- Habibullah JamalRye Brook$179K
- Albert JenFlushing$171K
- Dennis KrausNew York$159K
- Sveta KarelskyRochester$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.